Novolog Mix 70/30 Penfill Patent Expiration

Novolog Mix 70/30 Penfill is a drug owned by Novo Nordisk Inc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 19, 2017. Details of Novolog Mix 70/30 Penfill's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538

(Pediatric)

Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

Expired
US5866538 Insulin preparations containing NaCl
Jun, 2017

(7 years ago)

Expired
US5618913

(Pediatric)

Insulin analogues
Dec, 2014

(9 years ago)

Expired
US5618913 Insulin analogues
Jun, 2014

(10 years ago)

Expired
US5834422 AspB28 insulin compositions
Sep, 2013

(11 years ago)

Expired
US5840680 ASPB28 insulin crystals
Sep, 2013

(11 years ago)

Expired
US5547930 AspB28 insulin crystals
Sep, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Novolog Mix 70/30 Penfill is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Novolog Mix 70/30 Penfill's family patents as well as insights into ongoing legal events on those patents.

Novolog Mix 70/30 Penfill's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Novolog Mix 70/30 Penfill's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 19, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Novolog Mix 70/30 Penfill Generics:

There are no approved generic versions for Novolog Mix 70/30 Penfill as of now.

Novolog Mix 70/30 Penfill Alternatives

Novolog Mix 70/30 Penfill which is used for managing diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Novo Nordisk Inc
Novolog Mix 50/50

(uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant)

Used for managing diabetes mellitus.
Novolog Mix 70/30

(uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant)

Used for managing diabetes mellitus.
Novolog Mix 70/30 Flexpen

(uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant)

Used for managing diabetes mellitus.
Sanofi Aventis Us
Apidra used for managing diabetes mellitus.
Apidra Solostar Used for improving glycemic control in diabetes mellitus patients.





About Novolog Mix 70/30 Penfill

Novolog Mix 70/30 Penfill is a drug owned by Novo Nordisk Inc. It is used for managing diabetes mellitus. Novolog Mix 70/30 Penfill uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as an active ingredient. Novolog Mix 70/30 Penfill was launched by Novo Nordisk Inc in 2001.

Approval Date:

Novolog Mix 70/30 Penfill was approved by FDA for market use on 01 November, 2001.

Active Ingredient:

Novolog Mix 70/30 Penfill uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant ingredient

Treatment:

Novolog Mix 70/30 Penfill is used for managing diabetes mellitus.

Dosage:

Novolog Mix 70/30 Penfill is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) INJECTABLE Discontinued SUBCUTANEOUS